Journal of Drug Assessment

Journal of Drug Assessment 由 Taylor & Francis Group 出版。按 OpenAlex 近年发文统计，该刊主要发表 Pharmacy and Medical Practices、Pharmaceutical Practices and Patient Outcomes、Medication Adherence and Compliance 等主题的论文，这 3 个主题约占 35.8%。（根据 OpenAlex 主题统计与中科院分区数据生成）

This journal has ceased (2023). The Journal of Drug Assessment is an open access journal that publishes study types on a range of drug therapeutics of interest to the clinical medicine and research communities. The journal aims to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The journal’s objective is to help facilitate improvements in patient health by facilitating a collaborative and honest approach to publication. The journal welcomes smaller studies, preliminary and pilot studies, results from trials that have not met their endpoints and studies with confirmatory findings from Phase I–Phase IV trials. It also welcomes review articles and meta- The journal’s scope — combined with the transparent and rigorous peer review process — make certain that papers are accepted based on their scientific merit (i.e., technically sound, well-written, comprehensive reports), not on the novelty or impact of the results. In addition, the rapid publication timeline allows for online publication within 7-9 weeks of submission, whilst always ensuring total transparency of the peer-review process and disclosure of financial and other relevant relationships for all submitted manuscripts. The Journal of Drug Assessment publishes: Smaller and lower-impact studies and early trial data Null or negative study results in addition to incomplete, inconclusive or controversial results Confirmatory studies and updates to previous research Case studies in clinical practice, involving new and existing drugs Reviews on new and existing drugs, novel study designs, research and pharmacoeconomic outcomes Full-length original articles and meta-analyses that report the results of Phase I–IV studies on pharmaceutical products and medical devices in all drug classes, therapeutic areas and disease states (including approved and unapproved products, therapeutic diagnostic/theranostic products and over-the-counter medicines) Brief research reports that meet the above criteria and have the same elements as a full-length paper, but are shorter, and provide more concise information in each element, with fewer illustrations Editorials commenting on new developments in pharmaceutical regulatory affairs, new policies, health outcomes and drug manufacturing, and controversial clinical and preclinical findings Letters to the Editor as correspondence to the Editor on previously published work The journal operates a single-blind peer review p

摘自期刊官网 Aims & Scope

研究方向（LetPub）：PHARMACOLOGY & PHARMACY

中科院期刊分区表

数据库收录

收录数据库：暂无记录。

预警 / 风险提示：预警提示：2024年02月21日被ESCI期刊列表Cease停刊处理 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中LetPub

期刊官网自述收录

MEDLINEPMCEmbaseCINAHL出版商官网

期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子（出版商公布） 2022

2.4出版商官网 · 2026-11-01

五年影响因子（出版商公布） 2022

3出版商官网 · 2026-11-01

h-index

26OpenAlex · 2026-11-01

i10-index

62OpenAlex · 2026-11-01

两年平均被引

0OpenAlex · 2026-11-01

Gold OA 文章占比

100%LetPub · 2026-11-01

发文规模

年文章数

3LetPub · 2026-11-01

年下载量（出版商公布）

49,000出版商官网 · 2026-11-01

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

平均审稿速度（社区反馈）

8 WeeksLetPub · 2026-11-01

录用率（出版商公布）

29%出版商官网 · 2026-11-01

评审方式

盲审LetPub

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Taylor & Francis Group

出版国家或地区

United Kingdom

出版语言

English

ISSN

1369-9474

电子版 ISSN

2155-6660

官网最新一期

Volume 12, Issue 1（2023 年）

官方链接

• 期刊主页 ↗LetPub
• 作者指南 ↗LetPub
• Aims & Scope ↗LetPub
• 专刊 / 特刊征稿 ↗出版商官网
• 评审流程 ↗LetPub
• 编委会 ↗LetPub